Congress has passed a short-term spending package that will fund the government through February 8, 2018, and allow the FDA to resume normal operations.
Congress has voted to end the US government shutdown. The passage of the short-term spending package will fund the government through February 8, 2018.
The short-term funding agreement is welcome among agencies such as the FDA, which placed nearly half of its staff on furlough during the 3-day shutdown, and paused all work outside “activities necessary to address imminent threats to the safety of human life and activities funded by carryover user fees.”
Though the government has attained funding to carry on with its activities through the next few weeks, the potential for a second government shutdown—one that could potentially be longer than the first—remains overhead after February 8.
For the FDA, government shutdowns have widespread ramifications that can threaten the health and safety of millions of Americans. In the 2013 shutdown, nearly all of the agency’s food safety inspections ceased, along with most of its lab research aimed at informing public health decisions, as did agency efforts to keep drug labelling accurate and up to date.
Margaret Hamburg, MD, FDA Commissioner during 2013, told STAT that the drug approval process was also impacted by the shutdown: “As you know, [industry-funded] programs could continue, but there were delays, advisory committee meetings had to be canceled, review teams were juggling many more tasks [and therefore] less focused and responsive.”
Current FDA Commissioner Scott Gottlieb, MD, said that the agency was be better equipped in the most recent halt in operations than it was in previous shutdowns, and tweeted that the agency has access to carryover user fee funds that allow the agency to continue to review and approve some types of medical products applications.
However, during a shutdown, the government is less capable of carrying out research, addressing issues like drug and device shortages, and monitoring and responding to disease outbreaks.
In terms of financial impact, during every previous shutdown, Congress has allocated back pay for all furloughed federal employees. Thus, shutdowns don’t save the federal government any money, in fact, the 2013 shutdown reportedly cost the government $24 billion, according to the ratings agency Standard & Poor’s.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.